ABCD of ATTR Amyloidosis A PRACTICAL APPROACH: ATTR Amyloidosis **B**est Practices for Care and Diagnosis CCC accredited symposium

THURSDAY, OCTOBER 24th, 2019 12:30 pm to 1:30 pm 517C, Level 5, Palais des congrès de Montréal

LEARNING OBJECTIVES:

- Apply best practices for the diagnosis and treatment of amyloidosis
- Understand the importance of a coordinated multidisciplinary care approach
- Describe imaging modalities for the diagnosis and treatment of cardiac amyloidosis
- Understand the effect of amyloidosis on the nervous system and recognize when to refer to a neurologist and geneticist
- Discuss contemporary data and evidence in the context of the Canadian healthcare system

TIME	ΤΟΡΙϹ	SPEAKER
12:30 – 12:35 p.m.	Welcome and Introductions	Dr. Shelley Zieroth & Dr. Anique Ducharme (co-chairs)
12:35 – 12:55 p.m.	Emerging strategies to treat and manage amyloidosis	Dr. Sarah Cuddy
12:55 – 1:05 p.m.	Using imaging to guide therapy in cardiac amyloidosis	Dr. Jeroen Bax
1:05 – 1:15 p.m.	When ATTR gets on your nerves: A primer on ATTR neurologic involvement for cardiologists	Dr. Vera Bril
1:15 – 1:25 p.m.	CCS-CHFS Position Paper on Amyloidosis	Dr. Margot Davis
1:25 – 1:30 p.m.	Closing Remarks	Co-chairs
*Diana anta E min OSA will be dedicated disease in an anta the		

*Please note a 5 min. Q&A will be dedicated after each presentation



Canadian Heart Failure Society Société canadienne d'insuffisance cardiague







Shelley Zieroth **CO-CHAIR** MD, FRCPC, FCCS WINNIPEG, MB



Anique Ducharme CO-CHAIR MD, MSC MONTREAL, QC



Jeroen Bax MD. FESC LEIDEN, NETHERLANDS



Vera Bril MD, BSc, FRCPC TORONTO, ON



Sarah Cuddy MB BCh BAO BOSTON, MA



Margot Davis MD, SM, FRCPC VANCOUVER, BC

This event is an accredited Group Learning Activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was developed by the Canadian Heart Failure Society and was planned to achieve scientific integrity, objectivity and balance. This program was made possible through educational grants from Akcea, Alnylam and Pfizer Canada.